An observational study in Uveitis, sponsored by National Institute of Health, Korea. Completed. Per ClinicalTrials.gov, last updated 2013-04-22.
Sponsored by National Institute of Health, Korea · Observational
Investigate the prevalence of Toxoplasma gondii and Toxocara canis in Uveitis
Consecutive patients with uveitis are enrolled in Nune Eye Hospital.
Serum ELISA
PCR
questionnaire
335 studies on the registry are indexed under Uveitis; 37 are open to participants now.
This study's enrollment of 98 is close to the median of 100 across 107 observational studies indexed under Uveitis.
Browse Uveitis studies →This is the only study on the registry with National Institute of Health, Korea as lead sponsor.
Counted across the registry records on this site, refreshed daily.
patient with uveitis
Exclusion Criteria:
Number of patients with positive result for serum antibody to Toxoplasma gondii and Toxocara canis
proportion of patients with seropositive for Toxoplasma gondii and Toxocara canis among patients
Time frame: at baseline
Number of patients with positive PCR with peripheral blood and aqueous humor to Toxoplasma gondii and Toxocara canis
Proportion of patient with positive PCR to Toxoplasma gondii and Toxocara canis
Time frame: at baseline
location of inflammation and fundus finding
location of inflammation * anterior or posterior or panuveitis fundus finding * granuloma in macular or periphery retina * pigmentation
Time frame: at baseline
Demographic characteristics
* Gender * Residence * Pet ownership * Habit of eating uncooked meat
Time frame: at baseline
No study locations are listed for this record.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.